Clinical Efficacy of Amlodipine Besylate plus Irbesartan Hydrochlorothiazide in the Treatment of Elderly Hypertensive Patients with Concomitant Diabetes
Clinical Efficacy of Amlodipine Besylate plus Irbesartan Hydrochlorothiazide in the Treatment of Elderly Hypertensive Patients with Concomitant Diabetes
Objective:To analyze the clinical efficacy of amlodipine besylate combined with irbesartan hydrochlorothiazide in elderly patients with hypertension and diabetes.Methods:Ninety elderly patients with hypertension and diabetes admitted to our hospital were randomly divided into two groups,with 45 patients in each group.All patients received dietary adjustments,exercise recommendations,and routine glucose-lower-ing therapy.The control group was treated with amlodipine besylate alone,while the observation group received a combination of amlodipine besylate and irbesartan hydrochlorothiazide.After an 8-week treatment course,systolic blood pressure(SBP),diastolic blood pressure(DBP),blood glucose levels,lipid profiles,and ad-verse reactions were compared between the two groups.Results:Post-treatment,there were significant differ-ences in DBP and SBP between the two groups(P>0.05),with the observation group showing lower values.Fasting plasma glucose,2-hour postprandial blood glucose(2hPBG),and glycosylated hemoglobin(HbA1c)were also lower in the observation group compared to the control group(P<0.05).Total cholesterol,triglyc-erides,and low-density lipoprotein levels were reduced more significantly in the observation group(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination therapy of amlodipine besylate and irbesartan hydrochlorothiazide in elderly pa-tients with hypertension and diabetes demonstrated significant therapeutic effects and high safety profile.
维普
万方数据